Audentes Therapeutics Announces Plans to Commence Patient Dosing with AT702 in Q4 2019
Audentes Therapeutics has announced plans to commence patient dosing in the fourth quarter of 2019 with AT702 produced by Nationwide Children’s Hospital. AT702 is designed to induce exon 2 skipping to treat Duchenne caused by…Learn More